Cullinan Therapeutics, Inc. CGEM
15.75 USD +0.82 (+5.49%)
At closeNov 3, 2026, 4:00 PM EST
15.98 +0.23 +1.46%
After hours · Nov 3, 4:00 PM ET
14.98 Day range 16.20
6.73 52-week range 23.19
- YTD
- +52.17%
- 1 year
- +101.66%
Financial health
Altman Z-Score
10.26 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 2
Valuation
P/E -2.8×
FY 2018 5y median -2.8× FY 2025
P/S 0.0×
FY 2018 5y median 0.0× FY 2025
P/B 1.5×
FY 2018 5y median 1.1× FY 2025
P/FCF -3.5×
FY 2018 5y median -3.7× FY 2025
EV/EBITDA -2.4×
FY 2018 5y median -2.5× FY 2025
EV/Sales 0.0×
FY 2018 5y median 0.0× FY 2025
FCF Yield -28.8%
FY 2018 5y median -26.8% FY 2025
Profitability
Gross Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2018 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2018 5y median 0.0% FY 2025
ROE -53.8%
FY 2018 5y median -28.4% FY 2025
ROIC -58.7%
FY 2018 5y median -33.2% FY 2025
ROA -49.0%
FY 2018 5y median -26.9% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2018 FY 2025
Operating Income -22.7%
FY 2018 FY 2025
EPS (diluted) -19.6%
FY 2018 FY 2025
Free Cash Flow -21.0%
FY 2018 FY 2025
Financial Health
Current Ratio 10.2×
FY 2018 5y median 17.1× FY 2025
Quick Ratio 10.2×
FY 2018 5y median 17.1× FY 2025
Debt / Equity 0.0×
FY 2018 5y median 0.0× FY 2025
Net Debt / EBITDA 0.4×
FY 2018 5y median 0.5× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31